Molnupiravir Dosing in CKD Stage 4
No dose adjustment is required for molnupiravir in patients with chronic kidney disease stage 4 (eGFR 15-29 mL/min/1.73 m²); administer the standard dose of 800 mg orally every 12 hours for 5 days.
Evidence Basis
The standard molnupiravir regimen does not require modification based on renal function, even in severe renal impairment. This recommendation is supported by pharmacokinetic studies demonstrating that renal excretion is not the primary elimination pathway for molnupiravir or its active metabolite N4-hydroxycytidine (NHC) 1.
Pharmacokinetic Considerations
Key Findings from Renal Impairment Studies
- In the formal phase 1 renal impairment trial, participants with severe renal impairment (eGFR <30 mL/min/1.73 m²) receiving 800 mg molnupiravir showed 90% confidence intervals for NHC plasma AUC geometric mean ratios <2.0 compared to healthy controls 1
- Peak plasma concentrations and overall exposure were comparable between those with severe renal impairment and healthy participants 1
- Urinary excretion of NHC was low in both healthy participants and those with severe renal impairment, confirming minimal renal elimination 1
Important Caveat for Stage 5 CKD
While no dose adjustment is needed for stage 4 CKD, emerging data suggest caution in stage 5 CKD (eGFR <15 mL/min/1.73 m²). One pharmacokinetic study found that a patient with stage 5 CKD exhibited markedly elevated NHC plasma concentrations (1,600 ng/mL at 12 hours post-dose, equivalent to Cmax levels), suggesting potential drug accumulation 2. However, this represents limited data from a single patient.
Clinical Experience and Safety
Real-world evidence supports the safety of standard dosing in advanced kidney disease:
- A cohort of 40 patients with advanced CKD or kidney failure (including hemodialysis patients) received standard-dose molnupiravir with no serious adverse events and only mild-to-moderate grade 1-2 adverse events documented 3
- In kidney transplant recipients and hemodialysis patients, molnupiravir 800 mg every 12 hours for 5 days was well-tolerated with rapid symptom improvement within 24-48 hours and no drug interactions with immunosuppressive medications 4
- All patients in these cohorts survived >30 days, with only 3% mortality prior to 90 days 3
Practical Administration
- Dose: 800 mg orally every 12 hours
- Duration: 5 days (10 doses total)
- Timing: Initiate as early as possible after COVID-19 diagnosis, ideally within 5 days of symptom onset
- Monitoring: No specific pharmacokinetic monitoring required for stage 4 CKD
- Food: Can be taken with or without food
When to Exercise Additional Caution
Consider more intensive monitoring or alternative therapy if:
- Patient has stage 5 CKD (eGFR <15 mL/min/1.73 m²) not yet on dialysis, where limited data suggest possible accumulation 2
- Patient develops new symptoms that could represent drug toxicity during treatment
- Concurrent use of other medications with narrow therapeutic indices that could be affected by potential drug accumulation
The evidence consistently demonstrates that molnupiravir's elimination is predominantly non-renal, making it a practical oral antiviral option for patients with stage 4 CKD without the need for dose modification 1, 3.